ENXTBR:KBC
ENXTBR:KBCBanks

How Investors Are Reacting To KBC Group (ENXTBR:KBC) Strong Q3 Earnings and Profitability Gains

KBC Group NV reported third quarter and nine-month earnings for the period ended September 30, 2025, with net income rising to €1.00 billion for the quarter and €2.57 billion for the nine months, both higher than the same periods last year. The company's earnings per share from continuing operations also increased over both periods, reflecting improved profitability and operational performance. We'll assess how the jump in net income and earnings per share informs KBC Group's ongoing...
ENXTBR:SOLB
ENXTBR:SOLBChemicals

Will Solvay's (ENXTBR:SOLB) Rare Earth Deal Reveal Its Edge in Sustainable Supply Chains?

Noveon Magnetics and Solvay recently announced a multi-year supply agreement for light and heavy rare earth oxides, with Solvay providing Neodymium-Praseodymium, Dysprosium, and Terbium oxides, sourced partly from recycled materials, to support Noveon's production of permanent magnets starting in 2026. This collaboration advances a more resilient and sustainable domestic supply chain for rare earth magnets amid ongoing global supply risks and growing demand. The agreement enhances Solvay's...
ENXTBR:UCB
ENXTBR:UCBPharmaceuticals

A Look at UCB (ENXTBR:UCB) Valuation Following FDA Approval of KYGEVVI for TK2d

UCB (ENXTBR:UCB) received FDA approval for KYGEVVI, marking a major step in rare disease treatment. KYGEVVI is the first approved therapy for TK2d, a life-threatening mitochondrial disorder with very limited options. See our latest analysis for UCB. Following the FDA approval for KYGEVVI, UCB's momentum has been building. The share price has climbed nearly 20% year-to-date. After some short-term volatility, the stock's 1-year total shareholder return stands at an impressive 26%. Those who...
ENXTBR:SYENS
ENXTBR:SYENSChemicals

Syensqo (ENXTBR:SYENS) Is Up 7.1% After Swinging to Profit Despite Lower Sales—What’s Changed?

Syensqo reported third quarter 2025 earnings, revealing sales of €1.56 billion and net income of €39 million, compared to a third quarter net loss in 2024, despite a year-on-year decline in revenue for both the quarter and nine months ending September 30. The company’s rebound to profitability in the third quarter, following a loss a year earlier, underscores a shift in its performance trend even amid lower sales. We’ll assess how Syensqo’s return to quarterly profit, despite weaker sales,...
ENXTBR:LOTB
ENXTBR:LOTBFood

Does Lotus Bakeries' Euronext 150 Inclusion Signal a New Phase for ENXTBR:LOTB Investors?

Lotus Bakeries was recently added to the Euronext 150 Index, highlighting its growing profile among Europe’s largest listed companies. This milestone can influence share demand as index-tracking funds and institutional investors may adjust holdings to include the company. We’ll now explore how inclusion in a major index could impact Lotus Bakeries’ investment narrative and future institutional interest. AI is about to change healthcare. These 32 stocks are working on everything from early...
ENXTBR:ABI
ENXTBR:ABIBeverage

The Bull Case For Anheuser-Busch InBev (ENXTBR:ABI) Could Change Following $6 Billion Buyback and Leadership Shift

Anheuser-Busch InBev announced a US$6 billion share repurchase program and released its third quarter 2025 earnings, reporting sales of US$15.13 billion and net income of US$1.05 billion for the quarter ended September 30, 2025. The board also approved an interim dividend, renewed a key services framework with its Asia-Pacific subsidiary, and disclosed the upcoming departure of its longstanding Chief People Officer, marking a period of significant corporate actions. We'll explore how the...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Does argenx’s Share Price Growth Reflect Its Value After Positive Drug Developments?

Wondering if argenx is really worth its soaring share price? You are not alone, especially as buzz grows around how this stock stacks up against market expectations. argenx has delivered an impressive 30.8% return over the past year and is up 18.4% year-to-date, drawing fresh attention from growth-focused investors. Fueling recent price moves, the company has been in the spotlight due to positive new drug developments and regulatory wins that reinforce the long-term growth story behind the...
ENXTBR:KIN
ENXTBR:KINEntertainment

European Stocks Trading Below Estimated Intrinsic Values

As the European market navigates a mixed landscape, with the STOXX Europe 600 Index recently pulling back after reaching new highs and interest rate expectations from the ECB remaining steady, investors are increasingly focused on identifying opportunities among undervalued stocks. In such an environment, a good stock is often characterized by its potential to trade below its estimated intrinsic value, offering room for appreciation as market conditions evolve.
ENXTBR:SYENS
ENXTBR:SYENSChemicals

Syensqo (ENXTBR:SYENS): Exploring Valuation as Shares Draw Fresh Investor Attention

Syensqo (ENXTBR:SYENS) shares moved modestly today, catching the eye of investors who are watching for shifts in valuation. The stock’s recent performance offers an interesting angle for those tracking the materials sector. See our latest analysis for Syensqo. Syensqo’s share price has shown some resilience lately, notching a 5.9% gain over the past month and a modest 1-year total shareholder return of 0.6%. While momentum has been somewhat uneven, today’s movement suggests that investors are...
ENXTBR:MELE
ENXTBR:MELESemiconductor

Are We Seeing the First Signs of Operational Strain at Melexis (ENXTBR:MELE)?

Melexis NV reported its third quarter 2025 results, showing sales of €215.29 million and net income of €27.53 million, both significantly lower than the same period a year ago. The contraction in sales and profit indicates the company may be encountering operational or market challenges over the year so far. We’ll examine how reduced earnings for the quarter are influencing Melexis’ investment narrative and outlook for operational momentum. The end of cancer? These 29 emerging AI stocks are...
ENXTBR:DEME
ENXTBR:DEMEConstruction

A Look at DEME Group's (ENXTBR:DEME) Valuation Following Landmark Brazilian Port Concession Win

DEME Group (ENXTBR:DEME) has won Brazil’s inaugural auction for a port access channel concession, in partnership with FTS Participacoes Societarias. This 25-year contract covers operations and expansion at the vital Port of Parana. See our latest analysis for DEME Group. DEME Group’s announcement of the major Brazilian port concession appears to have reignited market attention, with a strong 6.6% share price return over the past month after a mixed year. While year-to-date returns remain...
ENXTBR:ABI
ENXTBR:ABIBeverage

Anheuser-Busch InBev (ENXTBR:ABI) Profit Margin Rises to 12.2%, Reinforcing Bullish Valuation Narratives

Anheuser-Busch InBev (ENXTBR:ABI) posted a net profit margin of 12.2% for the most recent period, a jump from last year’s 9.9%. Over the past five years, the company has averaged 24.5% annual earnings growth, with current-year earnings up 20%. Although this is not as rapid as previous years, it is still growing. With analysts forecasting another 10.03% per year in earnings growth and the stock trading well below consensus fair value estimates, investors are likely to see the current...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

argenx (ENXTBR:ARGX) Profitability Confirms Strong Growth Narrative, But Valuation Debates Persist

argenx (ENXTBR:ARGX) has achieved a notable turnaround to profitability over the past year, posting high-quality earnings and sustaining a five-year annual earnings growth rate of 52.7%. Looking ahead, consensus forecasts point to annual earnings growth of 28%, outpacing the Belgian market’s 15.6% projection, while revenue is also expected to rise by 18.5% per year compared to an 8.4% market average. Investors are weighing these strong growth figures and recent profitability against...